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Abstract 
Obesity is increasingly common in individuals with chronic kidney disease (CKD). Being overweight or 
obese is associated with both the development and progression of kidney disease. Lifestyle interventions 
such as the use of very low-calorie diets (VLCD) are being used increasingly for patients with CKD despite 
warnings from manufacturers that they should be avoided or used with caution. Whilst these diets are 
effective and can induce rapid weight loss and suppress appetite, their use in patients with chronic and 
end stage kidney disease is more complex than in the general population. VLCD use in adults with kidney 
disease requires a more nuanced approach to prescription and closer monitoring for unintended side 
effects. This review describes the indications and clinical management of patients with CKD undertaking 
a very low-calorie diet and provides practical guidance regarding how to manage a VLCD, particularly for 
the latter stages of CKD. 
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2 
Abstract  1 
Title: A practical guide for the use of very low calorie diets in adults with chronic kidney 2 
disease. 3 
 4 
Obesity is increasingly common in individuals with chronic kidney disease. Being 5 
overweight or obese is associated with both the development and progression of kidney 6 
disease. Lifestyle interventions such as the use of very low-calorie diets (VLCD) are being 7 
used increasingly for patients with CKD despite warnings from manufacturers that they 8 
should be avoided or used with caution. Whilst these diets are effective and can induce rapid 9 
weight loss and suppress appetite, their use in patients with chronic and end stage kidney 10 
disease is more complex than in the general population. VLCD use in adults with kidney 11 
disease requires a more nuanced approach to prescription and closer monitoring for 12 
unintended side effects. This review describes the indications and clinical management of 13 
patients with CKD undertaking a very low-calorie diet and provides practical guidance 14 
regarding how to manage a VLCD, particularly for the latter stages of CKD.  15 
Keywords: Very low-calorie diet; weight loss; chronic kidney disease; end stage kidney 16 
disease; evidence-based practice  17 
Support: Nil to declare  18 
Financial disclosure: Nil to declare. 19 
Contributions: Research idea and study design: KL, SB, BL, MR. Each author contributed 20 
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integrity of any portion of the work are appropriately investigated and resolved. KL takes 23 
responsibility that this study has been reported honestly, accurately, and transparently and 24 
that no important aspects of the study have been omitted.  25 
3 
Introduction  1 
Overweight and obesity are closely linked to both the development of and progression of 2 
kidney disease 1. Well controlled studies have demonstrated that weight loss can reduce 3 
proteinuria and reduce deterioration of eGFR 2. For adults who have developed end stage 4 
kidney disease, the efficacy and safety of weight loss is less well established though 3. In 5 
practice, although no definitive guidelines exist, individuals with end stage kidney disease 6 
who are obese are significantly less likely to be referred for kidney transplantation surgery 4 7 
 8 
Lifestyle interventions such as the use of very low-calorie diets (VLCD) are being used 9 
increasingly for patients with chronic and end stage kidney disease. Traditionally these 10 
products (also known as very low energy diets, VLEDs) have been used to induce rapid 11 
weight loss by restricting dietary intake to less than ~800kcal (3300 kilojoules) per day 5. The 12 
severe energy restriction results in ketosis and ongoing suppression of appetite occurs 6. Their 13 
efficacy is well established, and when used as directed can result in weight loss of 1.5-2.5kg 14 
per week. This is considered to be the single most effective short term non-surgical weight 15 
loss intervention for obesity when used for up to 16 weeks 5.  VLCDs can also result in 16 
remission of Type 2 Diabetes 7. 17 
 18 
Unfortunately, the use of VLCDs in adults with chronic and end stage kidney disease is more 19 
complex than in the general population and requires a more nuanced approach to prescription 20 
and closer monitoring for unintended side effects. Evidence for the use of VLCDs in kidney 21 
disease is limited by the small number of studies and the small numbers of participants. 22 
Therefore, the aim of this paper is to provide practical guidance to the nephrology community 23 
on the use of VLCDs in adult patients with chronic and end stage kidney disease (CKD and 24 
ESKD).  25 
4 
Overview of the physiological mechanism inducing weight loss  1 
Weight loss occurs during a VLCD via the mechanism of ketosis. This is a benign metabolic 2 
state8 and differs from ketoacidosis. Ketoacidosis will only occur when insulin is 3 
insufficient8. Ingestion of < 800 kcal / 3000 kilojoules per day will induce ketosis 9,10. When 4 
accompanied by ongoing caloric restriction and less than 100g of carbohydrate per day, 5 
metabolism of fat stores will occur 8,10. During ketosis, adipose tissue is broken down into 6 
free fatty acids and glycerol. The free fatty acids are used for energy by organs such as the 7 
liver and muscles. The ketones generated include beta-hydroxybutyrate and acetoacetate 10 8 
and are used by the brain as a substrate for metabolism. The utilization of these ketone bodies 9 
has a protein sparing effect. More detailed information on this process is provided elsewhere 10 
8 10 11.  11 
 12 
Ketogenic diets for weight loss typically result in serum ketone levels around 0.33-13 
0.72mmol/L.  By comparison, ketone levels in diabetic ketoacidosis may be as high as 14 
25mmol/L11.  A diagnosis of ketoacidosis is suggested when ketone bodies are detected and 15 
glucose is >11.1 mmol/L 11 and significant acidosis (arterial pH < 7.3 or venous bicarbonate 16 
<15mmol/L)8.		17 
	18 
Overview of very low-calorie diet products    19 
In Australia, New Zealand, Singapore and Hong Kong, VLCDs are typically available over 20 
the counter without a prescription. The most effective form of the VLCD consists of three 21 
shakes per day (made with water) to replace all food intake. A small portion of ~2 cups of 22 
low carbohydrate vegetables may often accompany the shakes for both social reasons and to 23 
ensure adequate fibre intake. In addition, many VLCD products recommend consumption of 24 
1-2 teaspoons of oil to ensure adequate essential fatty acid intake. Some commercial versions 25 
5 
of VLCDs also provide an alternative low energy formulation to the shake in the form of a 1 
soup, bar or dessert. While VLCD products are usually supplemented with micronutrients, 2 
they are not nutritionally complete and therefore should not be used long term 5. It is 3 
recommended that VLCD products are not used unless the BMI is > 30kg/m2 or the BMI is  4 
>27 kg/m2 with obesity related complications 12.  5 
 6 
There are generally three phases of a VLCD program. The first phase is characterised as the 7 
intensive phase, whereby all meals and snacks are usually replaced by three VLCD products. 8 
In the healthy population, a high fluid intake of more than 2 litres of low calorie fluid or 9 
water is strongly encouraged to facilitate excretion of ketones13. This phase can last up to 12 10 
weeks. The second phase is often called a ‘controlled’ phase with 2 meals per day replaced 11 
with a VCLD product and one small low-calorie meal per day. The final phase is the 12 
maintenance phase. In this phase, individuals transition back to a pattern of healthy eating 13 
and substitute one meal per day with a VLCD product. They may have repeated periods of 14 
intensive phase use separated by periods of weight maintenance 9 15 
 16 
Nutritional considerations of VLCDs for adults with kidney disease 17 
The macronutrient composition of the most popular VLCD products do not vary greatly13,14. 18 
Table 1 highlights the composition of several commonly available products. The nutrients 19 
provided when consuming the recommended amount of VLCD products are compared to the 20 
evidence-based guidelines 15-17 for an adult of a 90 kg male (BMI 27 kg/m2) in Table 1. In the 21 
context of following a VLCD, it is appropriate that requirements for energy, fat and 22 
carbohydrate need not be achieved to achieve weight loss goals. As seen in Table 1, all 23 
products provide less than the recommended amount of fiber, and potassium (when additional 24 
serves of vegetables are excluded). However, meeting protein recommendations and fluid 25 
6 
requirements is far more challenging when individuals have CKD or ESKD. Importantly, 1 
evidence indicates that meeting protein targets is critical while following a VLCD so as to 2 
preserve fat free mass 5. A more detailed analysis of the two main VLCD products in 3 
Australia and New Zealand are contained in Supplementary Materials.   4 
 5 
Can VLCDs be used safely in CKD and ESKD ? 6 
Initial weight loss will occur in the form of a reduction in muscle glycogen stores and 7 
diuresis that will necessitate careful monitoring of goal dry weight in patients undertaking 8 
hemodialysis (note dry weight refers to the target weight after dialysis regardless of the 9 
BMI). To prevent muscle catabolism, the use of a VLCD program should always be 10 
accompanied by a program of physical activity where possible 9.  11 
 12 
Individuals with advanced kidney disease have limited capacity to handle acid loads and will 13 
not excrete ketones readily. Evidence regarding the safety of VLCDs in those with CKD can 14 
only be derived from the small number of studies available which included individuals with 15 
CKD. One recent large randomized controlled trial using VLCDs in obese adults with type 2 16 
diabetes (the DIRECT trial) provides some important evidence that VLCDs can be used 17 
safely in people with CKD7. Results from the DIRECT trial included participants with 18 
diabetes and CKD and no adverse outcomes were reported regarding worsening of acidosis in 19 
these patients 7.  20 
 21 
Another potential side effect specific to the CKD population that is of importance to 22 
clinicians includes hyperkalemia. In a study of 22 patients on hemodialysis therapy who 23 
participated in a 12 week VLCD program, 12 of the 22 subjects had at least one episode of 24 
7 
hyperkalaemia (>6.0 mmol/L) during the 12 weeks intensive phase. Potassium dialysate 1 
concentration was also reduced in 6 patients during the study period18. 2 
 3 
Other complications from VLCDs have been reported. This includes death. However, these 4 
deaths occurred in an era when the protein in the VLCD was not complete for essential amino 5 
acids, nor supplemented with micronutrients5. Because these products now contain all 6 
essential amino acids they are now considered nutritionally complete for healthy people and 7 
safe for use9. However, the VLCD product information suggests that these products should 8 
not be used or used cautiously in those with kidney disease due to altered electrolyte and 9 
fluid requirements. Individuals with CKD or ESKD and coexisting heart failure, recent 10 
myocardial infarction or unstable angina, porphyria or those that are pregnant, breast feeding 11 
or aged less than 18 year old should also avoid commencing VLCDs 19.  12 
 13 
Other medical conditions that can occur in individuals undertaking a VLCD are listed below. 14 
These side effects occur due to the rapid weight loss during a VLCD and include: 15 
• Gall stones – which may be prevented by including 1-2 teaspoons of oil per day or 16 
use of ursodeoxycholic acid 20. 17 
• Hyponatremia and hypokalemia- consideration of cessation of diuretic therapy and 18 
of resonium if prescribed may be required  19 
• Hypoglycemia – the very low carbohydrate intake of a VLCD will require 20 
amendment to the dose of insulin in those with diabetes and consideration of 21 
reduction in dose of sulfonylureas. A reduction in dose of sulphonylurea of 50% at 22 
commencement of the VLCD has been suggested. 13. 23 
8 
• Hypotension – an average reduction in systolic blood pressure of 8.1% and diastolic 1 
blood pressure of 8.6% is expected 21 and may require dose reduction in 2 
antihypertensive medications.  3 
• Gout – may be exacerbated by the transient increase in uric acid levels that occur in 4 
the first few weeks of a VLCD. The addition of allopurinol may be required.  5 
• Abnormal liver function – is common in many obese patients. Elevation of Alanine 6 
Aminotrasnferase (ALT), gamma-glutamyl transferase (GGT) and aspartate 7 
aminotransferase (AST) and the absence of significant elevations of bilirubin or ALP 8 
or findings of acute disease may not require further investigation or changes in 9 
dietary protocol. However, isolated elevations of bilirubin and/or ALP and GGT 10 
with a progressive elevation of hepatocellular enzymes suggest concurrent hepatic 11 
disease, such as hepatitis or pancreatitis and must be investigated 13. 12 
• Medication interactions- patients on lithium may experience changes in serum 13 
lithium levels due to sodium depletion and renal retention of lithium. Lithium levels 14 
should be monitored weekly, then bimonthly. See Table 2 for more detail.  15 
• Medications with a narrow therapeutic range – monitoring for deviations from the 16 
therapeutic ranges is recommended. This could include tacrolimus, sirolimus, and 17 
mycophenolic acid22 18 
 19 
What other side effects of VLCDs can be anticipated ? 20 
VLCDs are generally otherwise considered safe with only minor, transient side effects being 21 
observed. These side effects are a result of the rapid weight loss and ketosis and may include: 22 
sensitivity to cold, halitosis, constipation, headache, hair loss, irritability, postural 23 
hypotension, fatigue, muscle cramps and menstrual disturbances 13. These side effects are 24 
generally insufficient in magnitude or duration to warrant cessation of the program but should 25 
9 
be made apparent to the patient prior to commencement. Most symptoms are observed by 1 
patients to have disappeared by days 4-6. 2 
 3 
How effective are VLCDs in those with CKD or ESKD ? 4 
There are limited studies providing clinical evidence on the effectiveness of VLCDs in those 5 
with CKD. This may be in part due to the reservations held by clinicians previously regarding 6 
the side effects and dangers of severe energy restriction in this population 19. Despite the 7 
paucity of data some case series and case reports do exist, which report successful weight 8 
reduction and minimal reported adverse effects. Lassemillante et al 23 were able to 9 
demonstrate a median weight loss of 7% (range 5.2-11.4%) in one year with the use of a 10 
modified VLCD protocol in a small cohort of chronic haemodialysis patients with no 11 
significant side effects reported. Phosphate binders were continued as prescribed for all but 12 
for one patients in which binders were temporarily ceased for a medical procedure.  There 13 
was no report of use of potassium binding resins but adjustment to potassium dialysate 14 
concentration was reported for one patient.  Similarly, Friedman et al 24 were able to achieve 15 
an average weight loss of 14.2 kg in five patients with advanced diabetes nephropathy with 16 
the use of VLCD for a period of 12 weeks.  They observed a statistically significant 17 
approximate reduction of 12% in serum creatinine and cystatin C and a 36% non-statistically 18 
significant reductions in albuminuria and a non-significant increase in albumin.   In addition, 19 
improvements in glycaemia, hyperinsulinaemia and insulin resistance were noted. The only 20 
adverse side effect in this case series were a transient elevation in blood urea nitrogen and 21 
creatinine early in the diet that resolved after reducing anti- hypertensives.	In a recent study 22 
of 22 HD patients following a VLCD diet for 12 weeks, pre dialysis weight declined by an 23 
average of 0.91kg per week whilst mean waist circumference reduced by 10.5cm at 12 weeks 24 
compared to baseline.  Nine out of the 22 patients achieved a goal weight required to be 25 
10 
actively listed for kidney transplantation 18.	In another case report on the use of a VLCD in 1 
a haemodialysis patient, weight loss in the order of 72kg in 77 days was reported 25.		2 
 3 
What patient groups with CKD may benefit from a VLCD regimen ? 4 
Select groups of patients with CKD are likely to benefit from weight loss 26. This includes: 5 
• Patients with CKD stage 1-3 and a BMI > 30kg/m2 especially those with type 2 6 
diabetes 7 
• Those with CKD and a BMI > 30kg/m2 or an increased waist circumference that are 8 
potential candidates for kidney transplantation  9 
• Those with CKD and a BMI > 30kg/m2 or an increased waist circumference that are 10 
using weight loss as a strategy to delay progression of renal failure.  11 
• Patients with CKD stage 5 and a BMI > 30kg/m2 undertaking dialysis that are 12 
potential candidates for kidney transplantation  13 
• Patients with CKD stage 5 and a BMI > 30kg/m2 undertaking dialysis that may 14 
benefit from weight loss for other reasons e.g. improved mobility, reduced joint pain. 15 
 16 
As a general guide, Nephrologists should give serious consideration to any individuals who 17 
display poor motivation; poor adherence to their insulin regimen and / or dialysis 18 
prescription; those with financial restrictions and those who lack social support.  These 19 
factors place them at high risk of side effects, inadequate weight loss and a low likelihood of 20 
success. The Nephrologist should balance the benefits of weight loss with the risks that may 21 
be associated with embarking on a strict VLCD. 22 
 23 
What VLCD prescription is recommended ? 24 
11 
Recent guidance from a panel of clinical experts suggests that despite the paucity of scientific 1 
evidence, VLCDs are safe and efficacious in those with CKD but require close monitoring to 2 
prevent complications 27. It should be emphasized that due to differing nutrient requirements 3 
at each stage of CKD, there is no single VLCD prescription recommended. As a result, Table 4 
3 outlines three suggested VLCD prescriptions for those with CKD stage 1-2 13. The standard 5 
protocol of 3 VLCD shakes per day with 2 cups of low carbohydrate vegetables and 1-2 6 
teaspoons of oil is sufficient. In addition, liberal water intake (or intake of low-calorie 7 
beverages to minimise taste fatigue) is encouraged. In motivated individuals, this program 8 
can be continued for up to 12 weeks. It can also be repeated numerous times following 9 
review with the health care team. 10 
 11 
For those with Stage 3-5 CKD a modified program is required. Protein intake using the 12 
standard approach for Stage 1- 2 CKD is compromised and additional modifications are 13 
required to meet the varying protein needs of individuals with stage 3-5 CKD. Lassemillante 14 
et al 23 prescribed a modified low calorie diet for a small cohort of haemodialysis patients.  15 
The diet was implemented using a standardised protocol utilising meal replacements, aiming 16 
at the following prescription (i) protein 1.128 to 1.2g/kg per day16, (ii) potassium 1mmol/kg 17 
per day, (iii) phosphate 800-1000mg/day, and (iv) meet any fluid restrictions.  On average, 18 
the protocol prescription was ~1000 kcal / 4000 kJ and 100g protein per day.  This comprised 19 
of meal replacement shakes (Optifast) (x2 per day) and bars (x1 per day); 150g meat per day; 20 
1 cup low calorie vegetables; 1 serve of 15g carbohydrate food; 2 serves of low potassium 21 
fruits.  Established fluid restrictions were maintained. The median study length in this study 22 
was 364 days.  The most dramatic weight loss was noted in the first 8-12 weeks. In contrast, 23 
Friedman et al 24, used an adapted VLCD for weight loss in patients with advanced diabetic 24 
nephropathy for a period of 12 weeks.  Participants were advised to include 4 VLCD 25 
12 
products per day and one lean meal consisting of 2 serves of vegetables and 1 serve of protein 1 
and a daily multivitamin supplement.  The diet was composed of 75g protein and 800kcal/ 2 
3360KJ per day with all essential vitamins and minerals provided.  Carbohydrate content was 3 
restricted to less than 50g per day to induce ketosis and suppress appetite.  Based on these 4 
limited studies, a modified protocol is suggested as shown in Table 3. Low potassium 5 
vegetables and fruit can be included if required.  6 
 7 
What monitoring is required ? 8 
Standard VLCD protocols recommend regular, ideally fortnightly follow up 13, with 9 
additional medical monitoring for patients classified as high risk.  Patients are classified at 10 
high risk if they have a BMI > 27 kg/m2 with co-morbidities; have a BMI>35 kg/m2 and are 11 
taking prescribed medications during the VLCD; or are aged greater than 65years 13.  Based 12 
on these criteria, almost all patients with ESKD are likely to be classified at high risk. 13 
However, follow up at this level is often not practical 24. Utilising telehealth to provide 14 
ongoing motivation and monitoring in addition to regular blood testing seems a pragmatic 15 
compromise in an already unwell population. Regular case discussion and review such as 16 
with a team that includes the Nephrologist, dietitian, renal nurse, GP or Endocrinologist may 17 
also be useful. For patients undertaking dialysis, frequent review of goal dry weight for 18 
dialysis should be completed to avoid fluid overload. For patients with diabetes, additional 19 
blood glucose monitoring should occur after commencement to monitor for hypoglycemic 20 
events. Monitoring of waist circumference can be unreliable and inaccurate in very obese 21 
patients so it is recommended to be used with caution. Recommendations regarding the 22 
frequency and type of monitoring are adapted from clinical treatment protocol literature 13 23 
and are shown in Table 4. Liaison with the medical team is required to determine the 24 
13 
frequency of monitoring pathology such as uric acid, bicarbonate, vitamin D, and full blood 1 
counts.  2 
 3 
What other factors require consideration when using VLCDs in CKD and ESKD ? 4 
• Motivation and adherence level. Adherence to VLCDs can be incredibly 5 
challenging. This is not just because eating is a social activity but also is a pleasurable 6 
one. VLCDs should only be recommended to highly motivated patients with adequate 7 
family and social support 23. Recent qualitative research suggests that strategies such 8 
as structured reviews and support, early evidence of rapid weight loss, and knowledge 9 
of strategies about how to distract from temptations will enhance adherence 29. 10 
Anecdotal reports from patients indicate the intensive phase may actually be easier to 11 
adhere due to ketotic suppression of appetite rather than during later phases when 12 
ketosis is mild or not present at all. Suggestions to overcome common barriers to 13 
adherence are provided in Supplementary Materials.  14 
• Weight goals for dialysis.  Due to the rapid weight loss associated with use of a 15 
VLCD, patients should be monitored closely. It is important to regularly reassess dry 16 
weight for individuals undertaking dialysis so as to avoid the risk of fluid overload. 17 
• Protein needs. Will vary in patients with kidney disease depending on stage of CKD 18 
and dialysis method, Patients undertaking dialysis require protein in the order of more 19 
than 1.1g/ kg of adjusted body weight/ per day. An adjusted body weight refers to the 20 
nutrient requirements for an obese individual using a BMI of 26 kg/m2, which is the 21 
upper end of the healthy BMI range for an adult patient undertaking hemodialysis. 22 
• There is a lack of evidence about how to meet these additional protein requirements 23 
while following VLCDs. Some clinicians may choose to include an additional shake 24 
or a serve of protein rich foods (although this does add extra kilojoules).  Other 25 
14 
suggestions include adding protein powders such as Beneprotein™ (Nestle Nutrition, 1 
25 kcal / 105 kJ per scoop and 6 g protein). A new product on the Australian market 2 
called BodieZ Protein water™ may also be a useful addition by providing 30g protein 3 
in 500ml of fluid with negligible potassium, sodium and phosphate however will need 4 
to be included as part of the fluid allowance for fluid restricted patients.  5 
• Fluid requirements. Patients with ESKD are required to limit their fluid intake.  The 6 
VLCD prescription will need to be factored into the fluid allowance and patients 7 
should be advised that they need to maintain their fluid allowance whilst on the 8 
VLCD program.  Use of bars rather than shakes may facilitate compliance with the 9 
fluid restriction. 10 
• Binder. Phosphate binders may still be necessary for patients following the intensive 11 
phase of a VLCD. Monitoring of serum levels of phosphate for those at CKD stages 12 
3B-5D is important and should be accompanied by advice on adjustment of binders 13 
when required.   14 
• Dialysate bath strength. May require adjustment and ongoing monitoring for those 15 
undertaking hemodialysis due to the alterations in dietary sodium, potassium and acid 16 
load likely to be experienced.  Monitoring by the dialysis team is required.  17 
• Financial burden. VLCDs are not available on prescription and will impose a 18 
financial burden in the order of ~$50 AUD per week to maintain. Whilst this replaces 19 
all meals, for many patients this may prohibit commencement of a VLCD and 20 
potentially impact adherence. 21 
• Taste fatigue. This is a common complaint for many patients undertaking a VLCD. It 22 
is strongly recommended that patients be encouraged to consume the appropriate 23 
quantity and amount of low carbohydrate vegetables to support adherence. Examples 24 
of the nutritional composition of these foods are shown in Supplementary materials. 25 
15 
Fluids such as tea, herbal tea, coffee, soda water, low kilojoule mineral water, low 1 
kilojoule cordial, low kilojoule non-cola soft drinks, and low kilojoule jelly are all 2 
appropriate alternatives to water within the individual patient set fluid allowance. 3 
Chewing of artificially sweetened lollies and chewing gum may also assist with taste 4 
fatigue and the temporary effects of halitosis. However, these may have a laxative 5 
effect if consumed in excessive amounts and can cause abdominal discomfort and 6 
diarrhea  7 
• Recommencement of eating. Whilst the focus of VLCD is on rapid weight loss, it is 8 
just as important to identify behaviors and strategies that will facilitate successful 9 
recommencement of eating and long-term weight maintenance. Ongoing frequent 10 
contact with health professionals and a skilled multidisciplinary team led by a 11 
dietitian is associated with better results and should be encouraged.   12 
 13 
Case study: a tale of two patients. 14 
The following table (Table 5) describes two patients with CKD who have been referred for 15 
VLCD. The first step in the assessment of these individuals would be to ascertain their 16 
motivation and readiness to change. Given that cognitive impairment 30 and low health 17 
literacy 31 are also common in end stage kidney disease it would be important to ascertain 18 
how well each patient understands what is being recommended and what the implications of 19 
the VLCD prescription will be. Given Patient 1 has a history of noncompliance it would be 20 
pertinent to explore what the challenges to compliance may be. If these patients were to agree 21 
to trial the intense VLCD prescription with three shakes per day then adjustments to insulin 22 
will be required in patient 1, and to antihypertensives and diuretics in Patient 2.  Frequent 23 
review of dry body weight for dialysis will be required. Discussion about side effects such as 24 
hypoglycemia and dizziness would be required. Strategies to prevent constipation by 25 
16 
ensuring adequate intake of low carbohydrate vegetables, fruits, and salad items or via the 1 
use of a suitable fiber supplement would also be prudent. In the case of Patient 1, additional 2 
discussion would be required to determine how to obtain an adequate protein intake on a 3 
VLCD while undertaking haemodialysis. Options to meet protein targets could include the 4 
use of a VLCD protein supplement bar, which offers the additional benefit of extra protein 5 
while limiting fluid intake compared to using additional VLCD shakes, desserts or soups.   6 
 7 
Conclusion  8 
 9 
The use of VLCDs in patients with CKD provides additional challenges to the health care 10 
team.  However, with modifications to the protocol and careful monitoring and selection of 11 
the patient this can be a potentially successful alternative weight loss option for patients who 12 
wish to improve their health outcomes. 13 
 14 
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Table 1. Comparison of nutritional composition of common VLCD products (when used as 
three shakes per day) 
 





Stage 3-4 CKD 
EBG 
recommendation 
Stage 5 dialysis 
Calories / day 













59 59 53 295 295 
Protein (g/day) 54 59 38 63-84 92 
Fiber (g/day) 10.3 1.4 11.0 25-30g 25-30g  












51 56 45 <100 mmol <100 mmol 
Potassium 
(mmol/kg) 
58 44 54 <84 mmol * <84 mmol 
Phosphorus 
(mg/day) 
1140 1001 882 <1000mg <1000mg 
 
Legend: EBG: evidenced based guideline.; *indicates may be different depending on 
symptoms and/or biochemistry results. Table 1 adapted from information from Gibson et al 6. 
Energy requirements are adjusted and based on BMI 26 kg/m2 (84kg). Requirements for 
carbohydrate and fat are based on recommendations to consume a minimum of 45% of 
kilojoules from carbohydrate; less than 30% of kilojoules from fat 14. Protein intake for stage 
3-4 CKD is based on 0.75-1g/kg adjusted body weight 12; for stage 5 CKD protein intake is 
calculated using 1.1g/kg 24 for an adjusted body weight of 84kg.  Adjusted body weight refers 
to nutrient requirements for an individual with a BMI of 26 kg/m2, which is the upper end of 
the healthy BMI range for an adult patient undertaking hemodialysis.  
Table 2:  Medications and recommended adjustments in CKD for VLCD program 
 
Medication type Suggested adjustment 
Hypoglycaemic 
agents 
Sulphonylureas and insulin need to be reduced at the start of the program.  
Recommend review with GP/Endocrinologist before starting VLCD.  
Recommend blood glucose monitoring q.i.d per day.  Start VLCD on a 
weekend 
Insulin Insulin requirements will require adjustment.  
For patients aware of their carbohydrate to insulin ratio, a suitable dose 
adjustment to their basal insulin should be made.  A reduction in the basal 
should be considered due to a reduction in hepatic glucose production.  On the 
intensive phase, a 50% reduction dose is suggested a starting point.  However, 
patients should not withhold or significantly reduce the basal insulin dose 
without discussion with their diabetes specialist.  Basal insulin should never be 
completely ceased to avoid the risk of ketoacidosis.  
Patients on twice daily mixed insulin are usually best managed by changing 
the dose of insulin to a basal insulin at half the previous total dose. 
Antihypertensive 
agents 
Blood pressure decreases with weight loss. VLCDs have a diuretic effect and 
adjustment of diuretics at commencement of VLCD may be required. 
Lipid lowering 
drugs 
Monitor and decrease unless familial hyperlipidemia 
Warfarin Monitor INR for deviations from the therapeutic range as intake of Vitamin K 
will alter compared to usual intake  
Digoxin Monitor for deviations from the therapeutic range  
Lithium Monitor level and thyroid function. Ensure adequate fluid intake 
 
Table 3. Suggested VLCD prescription and suitability according to stage of CKD 
 Intensive phase Controlled phase Maintenance phase 
CKD Stage 1-2 
 
 
Suitable for standard 
VLCD program 
3 shakes per day, 
2 cups low 
carbohydrate 
vegetables, 
liberal fluid intake & 




Provides: ~2970 kJ / 
710 kcal, 65g protein, 
18 g fiber, 31 mmol 
Na, 92 mmol K, 986 





2 shakes per day, 
1 light meal1, 1 serve 
dairy (~400 kJ /100 
Kcal or 150ml 
reduced fat milk), 1 
serve fruit (300 




Provides: ~ 3962 kJ/ 
947 Kcal, 72g 
protein, 19g fibre, 26 
mmol Na, 84 mmol 





1 shake per day, 
 2 light meals1,  
2 serves dairy (~400 
kJ /100 Kcal each or 
300ml reduced fat 
milk), 2 serves fruit 
(~300kJ / 70 Kcal 
each) & liberal fluid 
intake 
 
Provides: ~ 5475 kJ 
/1308kcal, 84g 
protein, 31g fibre, 
24mmol Na+, 
96mmol K+, 1148mg 
Ca, 1314mg P 
 
Monitor for 
constipation   
CKD Stage 3-4 
 
Stage 3 –  suitable for 
standard VLCD 
program with close 




Stage 4 – contact 
nephrologist to 
discuss suitability.  If 
suitable close 
monitoring of renal 
function, electrolytes 
and fluid status is 
recommended.  
3 shakes per day, 
2 cups low 
carbohydrate 
vegetables2, 
fluid intake as per 
medical team & 
1-2 teaspoon oil daily 
 
 
Provides: : ~2970 kJ / 
710 Kcal, 65g 
protein, 18 g fiber, 31 
mmol Na, 92 mmol 





phosphate level is 
outside the reference 
range. Monitoring of 
serum potassium is 
recommended. 
2 shakes per day, 
1 light meal1, 2 , 1 
serve dairy (~400kJ / 
100 Kcal or 150ml 
reduced fat milk),1 
serve fruit* (300 
kJ/70 Kcal) & fluid as 
per medical team 
 
Provides: ~3962 kJ / 
947 Kcal, 72g 
protein, 19g fiber, 26 
mmol Na, 84 mmol 





phosphate level is 
outside the reference 
range. Monitoring of 
serum potassium is 
recommended. 
1 shake per day, 2 
light meals 1, 2,  
2 serves dairy (~400 
kJ /100 Kcal each or 
400ml reduced fat 
milk ), 2 serves fruit 2, 
(~300 kJ / 70 Kcal 
each) & fluid as per 
medical team  
 
Provides: 5475 kJ 
/1308 Kcal, 84g 
protein, 31g fiber, 
24mmol Na+, 
96mmol K+, 1148mg 
Ca, 1314mg P  
Binders are 
recommended if 
phosphate level is 
outside the reference 
range. Monitoring of 








CKD Stage 5D 
 
Contact nephrologist 
to discuss suitability. 
Those not suitable 
may include those 
with poor motivation, 
poor adherence to 
their insulin regimen 
and /or dialysis 
prescription, those 
with financial 
restrictions and those 
who lack social 
support.  If suitable 
for commencement,  
close monitoring of 
electrolytes, fluid 
status, ideal dry 
weight is 
recommended 
4 shakes per day, 
1 cup low 
carbohydrate 
vegetables 2, 
fluid intake as per 
allowance & 
1 tsp oil daily. 
 
Alternatively, the 
patient could also use 
3 shakes per day and 
a dietitian prescribed 
portion of appropriate 
protein powder or 
protein water or high 
protein food. This 





Provides (based on 
for shakes per day): ~ 
3810KJ/912Kcal, 85g 
protein, 22g fiber, 
40mmol Na+, 
116mmol K+, 





phosphate level is 
outside the reference 
range. Monitoring of 




2 shakes per day,  
fluid intake as per 
allowance,  
1 light meal 2,3, 1 
serve dairy (~400 kJ 
/100 Kcal or 150ml 
reduced fat milk), 1 





82g protein, 19g 
fiber, 27mmok Na+, 
87 mmol K+, 1207mg 




phosphate level is 
outside the reference 
range. Monitoring of 




1 shake per day , 
fluid intake as per 
allowance,  
2 light meals 2,3, 1 
serve dairy (~400kJ 
/100 kcal or 150ml 
reduced fat milk), & 2 
serves of fruit 2 (~300 




104g protein, 31 g 
fiber, 25mmol Na+, 
102mmok K+, 





phosphate level is 
outside the reference 
range. Monitoring of 






Nutrient analysis based on Optifast use. Estimate of nutritional composition will vary 
depending on the type of food selected in the meal plan. 
1. Meal composed of 1-2 slice bread or up ½ cup rice or 1 cup pasta and 65g meat or 
chicken /or 130g fish and 2 cups low carbohydrate vegetables and 1-2 teaspoons of 
oil.  This would provide ~ 1500 kJ/357 Kcal 
2. At later stages of CKD the low carbohydrate vegetables and fruit may need to be low 
potassium choices. 
3.  Meal composed of 1-2 slice bread or up ½ cup rice or 1 cup pasta and 100g meat or 
chicken /or 130g fish and 2 cups low carbohydrate vegetables and 1-2 teaspoons of 
oil. This would provide ~ 1700 kJ/405 Kcal 
Table 4. Suggested monitoring during VLCD for patients with CKD  
 
 
Variable Baseline  
measurement 
Monitoring frequency after 
commencement of VLCD  
Anthropometry  
Weight* and BMI ✓ Every 2 weeks  
Waist circumference ✓ Every 2 weeks 
Clinical measures  
Blood pressure ✓ Every 2 weeks 
Biochemistry  
Electrolytes/urea/creatinine ✓ Every 2-6 weeks depending on 
CKD stage 
Serum bicarbonate  ✓ Every week in at risk patients 
(patients with diabetes requiring 
insulin).  
Calcium / Magnesium / Phosphate  ✓  Every 2-6 weeks depending on 
CKD stage 
Liver function tests ✓ Every 6 weeks 
Post prandial blood glucose level  ✓ Every 2 weeks or more frequently if 
hypoglycemia occurs 
Fasting glucose in those with diabetes ✓ Every 2 weeks 
Cholesterol/Triglycerides/HDL ✓ Every 6 weeks  
Uric acid 
 
✓ At discretion of medical team  
Full blood count ✓ At discretion of medical team 
Iron studies ✓ At discretion of medical team 
 
C Reactive protein  ✓ At discretion of medical team 
 
Variable Baseline  
measurement 
Monitoring frequency after 
commencement of VLCD  
1,25 hydroxy Vitamin D ✓ At discretion of medical team 
 
Thyroid stimulating hormone ✓ At discretion of medical team 
 
 
*Ideal dry weight may need frequent re-assessment to avoid fluid overload whilst on 
VLCD 
 
Table 5. Case study of two patients referred for VLCD prescriptions  
Patient 1, 51-year-old male undertaking 
haemodialysis 
Patient 2, 47-year-old female, Stage 3B 
CKD 
Referred for VLCD to be eligible for kidney 
transplant  
Referred for VCLD to reduce progression of 
CKD 
BMI 37 kg/m2 (weight 122kg)  BMI of 31kg/m2 (weight 87 kg) 
T2DM on insulin, retinopathy, gout, 
hyperlipidemia, cholecystectomy 
Hypertension, Glomerulonephritis  
Poor compliance with 1000ml fluid 
restriction and interdialytic weight gain more 
than 3L regularly. Does not test blood 
glucose levels regularly 
Many attempts at weight loss previously but 
unsuccessful  
Medications include Sevelemer 1 bd, 25 
units Insulin glargine (Lantus), insulin aspart 
(Novorapid)  5 units tds, Rosuvastatin, 
Darbepoetin alfa, calcium carbonate 1 tds, 
calcitriol, Ergocalciferol 
Medications include Metoprolol, 
Rosuvastatin, Ramipril, Clopidogrel, fish oil, 
Ergocalciferol, Spironolactone, vitamin B12 
Calculated requirements  
(Based on an adjusted weight of 92kg) 




Calculated requirements  
(Based on an adjusted weight of 75kg) 
Protein = 56-75g/day (0.75-1.0g/kg) 
Fluid=2615-3360ml/day (in absence of a 
fluid restriction) 
Potassium=75mmol/day (1mmol/kg) 
Phosphate= RDI recommended 
 
 
Supplementary Materials Table 1. Nutrition Profile of major VLCD products in Australia and New Zealand.  
























Optifast VLCD Shake (all flavours average) 53g 201 840 20 18.2 4.5 3.6 9.3 25 360 
Optifast VLCD Bar (Berry Crunch) 60g 238 1000 17.1 22.8 7.8 4.1 15.9 18 560 
Optifast VLCD Bar (cappuccino) 60g 235 990 17.1 22.2 7.7 4.2 15.9 18.5 570 
Optifast VLCD Bar (Cereal) 65g 201 890 18.2 22.1 5.2 2 17.6 17.6 550 
Optifast VLCD Bar (chocolate) 70g 228 950 17.8 17.8 7.6 8.4 10.9 22 525 
Optifast VLCD Soup (vegetable) 54g 201 840 20 18.2 4.5 3.6 33 25 360 
Optifast VLCD Soup (chicken) 48g 201 840 20 18.2 3.6 3.6 28.7 25 360 
Optifast VLCD Soup (tomato) 54g 201 840 20 18.2 3.6 3.6 31.5 20 360 
Optifast VLCD Dessert (all flavours) 46g 201 840 20 18.2 4.5 3.6 23.7 25 580 












Legend: Cals: Calories; kJ: kilojoules; CHO: carbohydrate; Na: sodium; K: potassium Po4: phosphate  
Item Serve 
Size 














Optifast VLCD Shake (all flavours average) 40 150 628.4 14.1 16.94 2 N/A 16.5 17.5 264.96 
Optislim VLCD Bars (cookies and cream) 60 214 896 19 17.6 7.4 0.7 16.1 14.3 476 
Optislim VLCD Bar (choc fudge) 60 215 900 18.5 17.2 7.6 1.1 16 16.8 508 
Optifast VLCD Bar (caramel crunch) 60 214 894 19.4 17.3 7.3 0.7 16.5 15 493 
Optifast VLCD Bar (berry crunch) 60 214 896 18.1 18.4 7.5 0.8 20.7 14.6 568 
Optislim Life Soup (creamy chicken) 50 206 860 15.4 20.2 7.2 N/A 27.5 13.6 250 
Optislim Life Soup (pumpkin) 50 205 856 14.3 21.7 3.6 N/A 27.5 13.6 250 
Optislim Life Soup (tomato) 50 206 862 15.3 21.4 2.1 N/A 19.4 13.6 250 
Supplementary Materials Table 2. Suggestions for managing adherence to a VLCD.  
Issue Suggestions for patients 
“Finding it difficult to 
prepare the VLCD 
diet at work” 
• Use a wide brim water bottle to mix up VLCD shakes 
• Try VLCD bars instead 
“I am used to having 
a snack between 
meals” 
• Halve a VLCD Bar and consume half at morning tea, the 
other half at afternoon tea and eat a salad or cooked 
vegetables at lunch 
• Include other snack items in between meals such as diet jelly, 
or low-carbohydrate, low potassium (where needed) 
vegetables  
• If you are undertaking the controlled or maintenance phase, 
include 1-2 pieces of fruit (use low potassium choices if 
needed); or a low-fat yoghurt (~150g) as a snack between 
meals 
• Drink adequate fluid within fluid restriction levels (where 
needed) and obtain an adequate sleep each night to make sure 
hunger signals are not signals of thirst or tiredness 
“I am just too hungry, 
it is too restrictive” 
• If the VLCD program is followed correctly, most people find 
appetite is controlled after the first week of the intensive 
phase  
• If additional carbohydrates are avoided, you should enter a 
state of ketosis and this will further reduce appetite 
• If struggling to stick to the program, a small portion of lean 
meat or fish can be included in the first week prior to the 
onset of ketosis to help manage hunger levels  
• Ensure hunger signals are not mistaken for cues to eat due to 
boredom or stress 
“I seem to have hit a 
plateau and my 
weight is not 
decreasing ” 
• Consider increasing exercise intensity to burn more calories 
or alternatively look at ways to increase daily activity levels. 
A pedometer is a useful tool to measure this 
• Individuals should try aiming for 8,000-12,000 steps per day, 
increasing up to this amount gradually from your current 
level of activity 
“I have too many 
social outings 
involving eating out 
and I don’t want to 
miss out on these” 
• Focus on the other aspects of socialising such as the people 
they are with and the location rather than focusing solely on 
the food and drink 
• Try having VLCD product prior to going out to reduce 
appetite and then choose low starch salad or vegetables (low 
potassium if needed)  
• Try stir-fry vegetables, or a garden salad with the dressing on 
the side (no creamy sauces). If possible, skip the 
carbohydrate foods on offer and have a small or no serve of 
protein.  
• Try omitting that VLCD shake or meal and opt for a small 
portion of protein such as 100g meat or chicken, some fish or 
eggs  
• Avoid alcohol - have a sparkling mineral water with a wedge 
of lemon or lime in it or a diet soft drink served in a 
champagne or wine glass 
• For patients undertaking the controlled or maintenance 
phases, choose grilled meat, chicken or fish with a side salad 
or cooked low starch vegetables 
• Always ask for the sauce / dressing to be omitted or placed 
on the side to control the amount that is put on the meal  
• Always choose your own meal, and if possible avoid 
banquets and sharing meals 
• If possible, get a copy of the menu prior to going out so you 
can take your time to review the menu options 
“I don’t want to 
consume shakes and 
salads in the cold 
weather ” 
• Try making Shakes with warm water (not boiling) or can try 
the VLCD Soups 
• Consume cooked vegetables instead of salad (low potassium 
if needed) 
• Make your own low-calorie soup from the allowed 
vegetables (use low potassium if needed) 
“I am getting 
constipated” 
• Ensure all of the fluid allowed is consumed (within fluid 
restriction if needed)  
• Try to consume the recommended 2 cups of low starch 
vegetables per day 
• Exercise daily to help keep bowels healthy and regular 
• Consider using a fibre supplement such as Benefibre or 
laxative such as Movicol / Osmolax  
“Everyone around me 
is concerned that the 
diet is too strict” 
• Reassure your supporters that this program is supervised and 
effective.  
• Ask them to help exercise with you to facilitate weight loss  
• Consider if desired, moving between phases as your 
individual goals or lifestyle changes over time 
“It is too boring” • Vary the type of products used. Try shakes of all flavours, 
soups, bars and desserts with the serves of low carbohydrate 
vegetables and fruit.  
• Vary flavours for salads and vegetables by adding fresh or 
dried herbs and spices, and trying different types of low 
carbohydrate vegetables (use low potassium if needed)  
• Add different colours to the plate to help make the meal look 
appealing 
“I don’t seem to have 
enough energy” 
• High intensity exercise uses predominantly carbohydrates. 
During the intensive phase minimal amounts of 
carbohydrates are consumed; therefore, lower intensity 
exercise and weights may be easier for the individual.  
• Vary the time of day you exercise 
• Choose an exercise that you enjoy or exercise with a friend to 
improve motivation levels   
• Even if exercise intensity and duration is slightly reduced, 
some exercise is still better than none as it improves 
metabolism and helps preserve metabolic muscle tissue  
• Drinking sufficient fluids (within fluid restriction levels if 
needed) and getting adequate sleep will also help improve 
energy and motivation to exercise 
“I keep getting 
headaches” 
• This is normal in the first few days of the intensive phase and 
indicates the transition into ketosis.  
• Consider trialling an alternative phase eg controlled phase if 
unable to persist.  
“I’m not losing any 
weight” 
• This is very unlikely to occur during the intensive phase if 
followed correctly.  
• Consider adjusting ideal body weight for dialysis patients as 
this may suggest fluid overload if the individual is not losing 
weight and they are compliant with the prescription.  
• If the individual has not included regular exercise, then 
consider introducing gentle low intensity exercise. The 
combined effects of exercise plus a VLCD have been shown 

















Potassium         
(mmol) 
Phosphate   
(mg) 
Sprout, alfalfa, raw 100g 22 91 3.2 0.5 1.7 1.5 65 
Asparagus 50g 11 45 1.25 0.7 0.04 4 24.5 
Spout, bean, raw 100g 20 84 2.7 1.4 0.04 3.3 36 
Cabbage, bok choy, raw 50g 10 41 1.3 0.3 1.3 5 14 
Brussels sprout, fresh,  50g 18 75 1.9 1.05 0.65 5 Not listed 
Cabbage, white, raw 50g 13 54.5 0.8 1.7 0.33 3.7 20 
Capsicum, red, raw 100g 25 106 1.5 3.5 0.09 4.5 28 
Carrot, mature, peeled 50g 16 66 0.4 2.5 0.87 3.6 18 
Cauliflower, raw 50g 12 49.5 1.05 0.95 0.67 3.8 25 
Celery 50g 7.6 32 0.3 1.15 2.11 3.4 14.5 
Cucumber, Lebenese,  100g 12 51 0.4 1.9 0.83 3.4 44 
Eggplant, raw 100g 21 89 1 2.4 0.22 4 28 
Fennel, raw 50g 11 46 0.5 1.65 0.83 4 Not listed 
Garlic, peeled, raw 25g  31 131 1.5 2.55 0.09 3 Not listed 
Bean, green, fresh, raw 50g 15 61 1.2 1.35 0.04 2.8 21 
Konjac noodles  100g 10.5 44 0.1 <0.5 0.02 Not listed Not listed 
Lettuce, iceberg, raw 50g 4.8 20 0.5 0.2 0.57 2.6 12.5 
Mushroom, common  50g 12 52 1.65 0.7 0.17 4 55 
Onion, brown  100g 30 127 1.7 4.6 0.48 4 39 
Radish, red skinned 100g 15 62 0.8 1.9 0.87 4.6 20 
Shallot, peeled, raw 50g 12 52 0.8 1.6 1.17 2.9 17.5 
Silverbeet, raw 50g 8 35 0.8 0.55 4.6 3.6 17 
Snowpea, raw 50g 18 76 1.45 2.25 0.02 5 21 
Squash, button, raw 100g 26 110 2.7 3.2 0.04 3.6 Not listed 
Tomatoes, common,  50g 9 37 0.5 1.2 0.17 2.7 13 
Tomatoes, cherry, raw 50g 7.7 33 0.25 1.1 0.22 3 Not listed 
 
Nutrient composition data obtained from Food Standards Australia and New Zealand located at 
http://www.foodstandards.gov.au/science/monitoringnutrients/afcd/Pages/foodsearch.aspx 
  
